The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The potential of bispecific T-cell engagers targeting FLT3 in AML
In this video, Mohammad Maher Abdul-Hay, MD, NYU Langone Health, New York City, NY, briefly discusses the potential of using bispecific T-cell engagers targeting FLT3 for the treatment of acute myeloid leukemia (AML), highlighting that this approach can be utilized in both patients with mutated and wild-type FLT3, unlike commonly used FLT3-targeted agents. He also mentions the Phase I trial (NCT05143996) of CLN-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, which demonstrated encouraging results, including in patients harboring p53 mutations. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so in FLT3 targets like, say, Gilteritinib, Quizartinib, Midostaurin, you’re targeting only FLT3-mutated cells. This is a completely different approach here. This is a BiTE that’s targeting FLT3. You don’t have to be mutated FLT3 to have expression of your FLT3, 80% of myeloblasts express it. So you could target these patients even if they are wild-type FLT3...
Yeah, so in FLT3 targets like, say, Gilteritinib, Quizartinib, Midostaurin, you’re targeting only FLT3-mutated cells. This is a completely different approach here. This is a BiTE that’s targeting FLT3. You don’t have to be mutated FLT3 to have expression of your FLT3, 80% of myeloblasts express it. So you could target these patients even if they are wild-type FLT3. So it’s completely different. And it’s a phase one, early phase, but we saw some great responses in patients including p53. So we know p53 patients have actually the worst outcome, they’re so resistant to chemotherapy. And our last step-up dose cohort, we went to a high dose of 12 micrograms per kilogram. We had 50% of the patients with p53 mutation. And we saw 50% of these patients achieving CR and CRh. It’s an early phase, it’s just starting, but it looks like you can overcome even the toughest type of AML in this drug. So the future looks promising. I think in general, we’re understanding more about AML, we’re understanding the best way to approach and how to target it. But, you know, combination therapies and adding a BiTE to combination therapy, I think it could be a big, big potential for the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
